Frequentist and Bayesian pharmacometric-based approaches to facilitate critically needed new antibiotic development: overcoming lies, damn lies, and statistics.
about
EXpectation Propagation LOgistic REgRession (EXPLORER): distributed privacy-preserving online model learningThe evolution of the regulatory framework for antibacterial agentsEarly endpoints for acute bacterial skin and skin structure infections.White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogensDiscordant minimum inhibitory concentration analysis: a new path to licensure for anti-infective drugs.Recent Updates on the Role of Pharmacokinetics-pharmacodynamics in Antimicrobial Susceptibility Testing as Applied to Clinical Practice.Drug development challenges and strategies to address emerging and resistant fungal pathogens.Multicenter Study of Clinical Features of Breakthrough Acinetobacter Bacteremia during Carbapenem Therapy.Drug concentration monitoring in Mycobacterium avium lung disease: problems with methods and conclusions.Bayesian approach to the design and analysis of non-inferiority trials for anti-infective products.Statistical considerations associated with a comprehensive regulatory framework to address the unmet need for new antibacterial therapies.In silico-derived bedside formula for individualized micafungin dosing for obese patients in the age of deterministic chaos
P2860
Q28681721-B103969D-434F-4DD8-AD78-88F78F4EED44Q34693386-8D2AB601-28D6-4DF8-84AA-29664AAB3C5CQ35941449-CF87EA09-6BDD-482F-A6D0-94E2B379A6C6Q36854025-F2CB80EE-D809-4DA6-96FC-DB09663B840DQ37353682-177EE800-1373-469C-847F-1DCD05CA49EBQ38536299-E7F486D8-9E97-49F0-87B0-F696AC405616Q38798805-FB31F6E3-8966-431D-A9AB-568B8ED806F2Q39167693-3EF5FA52-E11C-4CBB-804B-95B1256AA2EDQ43489663-348FE3A0-40A7-4371-9C3D-26AD4E28EFD5Q43990228-C4BA1AEF-CEA1-4143-A59C-B075371112C0Q51079236-1BDE527A-5AF9-4300-B31B-F7AAD069CFB4Q58033439-E410FAC7-D1C0-42EA-9221-16A4C6D2E0A3
P2860
Frequentist and Bayesian pharmacometric-based approaches to facilitate critically needed new antibiotic development: overcoming lies, damn lies, and statistics.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Frequentist and Bayesian pharm ...... es, damn lies, and statistics.
@ast
Frequentist and Bayesian pharm ...... es, damn lies, and statistics.
@en
type
label
Frequentist and Bayesian pharm ...... es, damn lies, and statistics.
@ast
Frequentist and Bayesian pharm ...... es, damn lies, and statistics.
@en
prefLabel
Frequentist and Bayesian pharm ...... es, damn lies, and statistics.
@ast
Frequentist and Bayesian pharm ...... es, damn lies, and statistics.
@en
P2093
P2860
P356
P1476
Frequentist and Bayesian pharm ...... es, damn lies, and statistics.
@en
P2093
Christopher M Rubino
Evelyn J Ellis-Grosse
George L Drusano
Jeffrey P Hammel
Paul G Ambrose
Sujata M Bhavnani
P2860
P304
P356
10.1128/AAC.01743-10
P407
P577
2011-12-12T00:00:00Z